# HSK0935

**Cat. No.:** HY-101782

**CAS No.:** 1638851-44-1

**Molecular Formula:** $C_{22}H_{25}ClO_7$

**Molecular Weight:** 436.88

**Target:** SGLT

**Pathway:** Membrane Transporter/Ion Channel

**Storage:**

| | | |
|---|---|---|
| Powder | -20°C | 3 years |
| In solvent | -80°C | 6 months |
| | -20°C | 1 month |




## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 100 mg/mL (228.90 mM; Need ultrasonic)

| Preparing Stock Solutions | Mass / Solvent / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.2890 mL | 11.4448 mL | 22.8896 mL |
| | 5 mM | 0.4578 mL | 2.2890 mL | 4.5779 mL |
| | 10 mM | 0.2289 mL | 1.1445 mL | 2.2890 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an $IC_{50}$ of 1.3 nM. Antihyperglycemic activities [1].

**$IC_{50}$ & Target**

IC50: 1.3 nM (SGLT2)[1]

**In Vitro**

HSK0935 (Compound 31) demonstrates excellent hSGLT2 inhibition of 1.3 nM and a high hSGLT1/hSGLT2 selectivity of 843-fold[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**

HSK0935 treatment (1, 3, and 10 mg/kg) shows robust urinary glucose excretion in Sprague–Dawley (SD) rats and affects more urinary glucose excretion in Rhesus monkeys[1].

HSK0935 is well tolerated up to 300 mg/kg without any mortality or severe untoward effects in a 28-day repeat-dose toxicology study in beagle dogs[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Li Y, et al. Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes. J Med Chem. 2017 May 25;60(10):4173-4184.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA